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ed in this cohort. We observed biparental (recessive) inheri-
tance in 34% of mutation-positive patients, dominant inher-
itance in 11% and paternal transmission of a mutation asso-
ciated with a focal CHI type in 38%. In addition, we observed 
inheritance patterns that do not exactly follow the classical 
recessive or dominant mode, further adding to the genetic 
complexity of this disease.  © 2014 S. Karger AG, Basel 
 Introduction 
 Congenital hyperinsulinism (CHI) is a disorder of dys-
regulated insulin secretion resulting in persistent hypogly-
cemia with potentially harmful consequences. It manifests 
in nearly 50% of patients during the first hours or days of 
life  [1] . The prevalence in the EU population (calculated 
from 8 EU countries) is 1.85 per 10,000, and the incidence 
has been reported as 1: 40,000  [2] . CHI is characterized by 
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 Abstract 
 Congenital hyperinsulinism (CHI) causes hypoglycemia due 
to irregular insulin secretion. In infants, a rapid diagnosis and 
appropriate management to avoid severe hypoglycemia is 
mandatory. CHI is a heterogeneous condition at the clinical 
and genetic level, and disease-causing genes have been 
identified in about half of the patients. The majority of muta-
tions have been identified in the  ABCC8 and  KCNJ11 genes 
encoding subunits of the K ATP channel responsible for two 
distinct histological forms. The diffuse form is caused by au-
tosomal recessive or dominant inherited mutations, where-
as the focal form is caused by a paternally transmitted reces-
sive mutation and a second somatic event. We report on an 
unselected cohort of 136 unrelated patients from the 
 German CHI registry. Mutations in either the  ABCC8 or  KCNJ11 
gene were identified in 61 of these patients (45%). In total, 
64 different mutations including 38 novel ones were detect-
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clinical, histological and genetic heterogeneity (MIM 
600509, 600937, 138130, 138079, 256450), but common to 
all types are inappropriately elevated levels of insulin in 
relation to low plasma glucose concentrations along with 
low levels of fatty acids and ketones  [3, 4] . Diazoxide 
(DZX) is used as first-line medication, while in DZX-re-
sistant cases of CHI, off-label therapy with octreotide ana-
logues or glucagon has been used  [5, 6] . The most severe 
forms of CHI are caused by loss of function of the  ABCC8 
and  KCNJ11 genes encoding subunits of the ATP-sensi-
tive K ATP channel. This subgroup has been given the name 
channelopathies. They are usually associated with unre-
sponsiveness of pancreatic β-cells to medical treatment. 
Recently, it has been suggested to implement rapid genet-
ic analysis of  ABCC8 and  KCNJ11 in newborns with DZX-
unresponsive CHI to improve patient management  [7, 8] . 
Gene defects in medically responsive or partially respon-
sive CHI include mutations in  GLUD1, GCK, HADH, 
 SLC16A1, UCP2, HNF4A  and HNF1A  [9] .  This subgroup 
is due to dysregulation of the glucose-mediated signaling 
pathway promoting insulin release and is summarized as 
metabolopathies. Still, for more than 65% of children af-
fected by CHI the genetic basis is unknown and the mech-
anisms of disease remain to be determined  [10] .
 Four ABCC8 (sulfonylurea receptor 1) and 4 KCNJ11 
(Kir6.2) protein subunits form the K ATP channel as a het-
ero-octameric complex  [11] . The majority of CHI-associ-
ated mutations (e.g. nonsense, frameshift, splice site) are 
predicted to cause a loss of protein expression, while mis-
sense mutations may act through perturbed trafficking of 
the subunits to the plasma membrane or interference with 
the formation or the gating function of the channel  [12–
15] . Electrophysiological evidence of K ATP channel dys-
function has been identified in children with CHI muta-
tions due to either  ABCC8  or  KCNJ11  [16] . Recessive in-
heritance of 2 inactivating mutations leads to functionally 
impaired K ATP channels or their complete absence  [17] . 
In healthy heterozygote carrier parents, the wild-type al-
lele is sufficient to ensure the formation of intact channels. 
In contrast, dominant mutations are specific missense 
mutations in the  ABCC8 and  KCNJ11 genes which are 
presumed to be expressed as abnormal protein compo-
nents and to integrate into the hetero-octameric complex, 
where they interfere with the proper assembly or function 
of the channel (dominant negative effect)  [18] . In line 
with the proposed molecular mechanisms, biallelic inac-
tivating mutations of the  ABCC8 or  KCNJ11 gene are usu-
ally associated with a severe phenotype and resistance to 
treatment with DZX, a component that is able to bind to 
and modify the function of K ATP channels. In contrast, 
dominant-acting mutations are often associated with a 
less severe clinical expression and DZX sensitivity  [19] .
 Three histological CHI subtypes have been classified, 
which are commonly described as diffuse, focal and atyp-
ical forms  [20] . The diffuse form affects all pancreatic 
β-cells and is most frequently associated with biallelic in-
activating mutations in the  ABCC8 and  KCNJ11 genes 
and recessive inheritance of the disease. Occasionally, the 
diffuse form of CHI is caused by dominant-acting muta-
tions  [18, 19, 21] .
 In contrast, patients carrying only a paternally inher-
ited heterozygous loss-of-function mutation of  ABCC8 or 
 KCNJ11 are suspected to have a focal subtype of CHI, 
where only a circumscribed lesion of the pancreas is af-
fected. It has been proposed that in such a focus of dys-
regulated β-cells only the paternally transmitted mutant 
allele of  ABCC8 or  KCNJ11 is expressed while the mater-
nal allele is absent due to a second somatic mutation event 
 [22–26] . The circumscribed hypersecretion of insulin can 
be visualized by positron emission tomography/CT with 
increased [ 18 F]fluoro- L -3,4-dihydroxyphenylalanine up-
take compared to the unaffected pancreas  [27] . For these 
infants, limited pancreatectomy has been shown to be cu-
rative  [28, 29] .
 Herein, we report the clinical and mutational spec-
trum in a large patient cohort from the German CHI reg-
istry and analyze the data for genotype-phenotype corre-
lations.
 Materials and Methods 
 Patients 
 A total of 146 patients with the clinical diagnosis of CHI were 
referred between January 2005 and November 2012 for further dif-
ferential diagnosis and included in the registry. Patients belonged 
to 136 unrelated families originating from Central Europe (n = 
133), Asia (n = 1) and South America (n = 2). The cohort included 
125 sporadic cases and 21 kin with familial occurrence of CHI. CHI 
clinical diagnosis was based on recurrent hypoglycemia (<2.5 
mmol/l plasma glucose) with low plasma levels of ketone bodies 
and free fatty acid together with measurable insulin levels at the 
time of hypoglycemia. DZX treatment was started at 5 mg/kg/day 
by oral application of 3 separate doses per day. Doses were in-
creased up to 15 mg/kg/day if unresponsiveness was observed, i.e. 
glucose levels below 3.5 mmol/l. Written informed consent was 
obtained from the parents of the patients according to the approv-
al by the local ethics committee and in agreement with the German 
law on genetic testing.
 Sequence Analysis 
 The coding regions of all  ABCC8 exons and adjacent regions 
and the single exon of  KCNJ11 were analyzed by conventional 
Sanger sequencing. Oligonucleotide primer sequences and proto-
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cols are available on request. Sequence variants were compared 
with the Single Nucleotide Polymorphism Database and the se-
quence changes reported in the Human Gene Mutation Database 
(Cardiff, UK) and by Bellanné-Chantelot et al.  [30] , Flanagan et al. 
 [31] , Kapoor et al.  [32] and Snider et al.  [33] . If applicable, se-
quence changes observed in the index patients were further evalu-
ated in parents and further affected family members to confirm 
segregation with the phenotype. Novel missense mutations were 
scrutinized with the help of the in silico prediction programs Poly-
Phen-2  [34] and MutationTaster2  [35] , and novel frameshift, non-
sense and splice site mutations were analyzed with Mutation-
Taster2. 
 Multiplex Ligation-Dependent Probe Amplification Analysis 
 The  ABCC8 gene was further analyzed by multiplex ligation-
dependent probe amplification (MLPA) when sequencing re-
vealed a heterozygous or no causative mutation in  ABCC8 or 
 KCNJ11. The  ABCC8 MLPA kit (Kit 117, MRC Holland, Amster-
dam, Netherlands) was applied as recommended by the manufac-
turer. MLPA products were separated on a capillary sequencer and 
analyzed using Sequence Pilot software (JSI medical systems 
GmbH, Kippenheim, Germany). Deletions detected by MLPA 
were verified by analyzing the parental DNAs and by exon-span-
ning PCR and agarose gel electrophoresis to detect a fragment of 
reduced size.
 Results 
 In this patient cohort primarily composed of CHI pa-
tients from Germany and Central Europe, 53 different 
mutations were detected in the  ABCC8 gene ( fig.  1 a) 
and 11 different mutations were identified in the 
 KCNJ11 gene ( fig. 1 b). In total, causative mutations in 
one of the genes encoding components of the K ATP 
channel were identified in 61 out of 136 unrelated fam-
ilies (45%).
 Spectrum of Mutations Detected in the ABCC8 and 
KCNJ11 Genes  
 In the  ABCC8  gene, nonsense, frameshift and splic-
ing mutations (presumable ‘null’ mutations) accounted 
for about half of the mutations (24 out of 53), and they 
were dispersed throughout the gene. A highly recurrent 
mutation suggesting a founder effect was not observed. 
In contrast, missense mutations (n = 24) were located 
more frequently within exons 1–10 and 29–38, with half 
of them occurring in exons 34–38, which encode the sec-
ond nucleotide-binding domain of the sulfonylurea re-
ceptor 1 subunit ( fig.  1 a). This distribution pattern is 
quite similar to previously described patient cohorts 
 [30–33, 36, 37] . Three different in-frame deletions and 
2 different intragenic deletions encompassing exons 32 
and 33 and exons 34–37, respectively, were detected in 
unrelated patients. Most mutations were ‘private’, i.e. 
they were detected only in a single family. The most re-
current mutation, the previously described missense 
change p.Q444H, was observed in 5 unrelated families 
of our cohort. Nine of the 11 mutations detected in 
 KCNJ11  were missense mutations, including 8 novel 
changes, 1 mutation was a novel in-frame deletion of a 
single amino acid and 1 was a novel complex frameshift 
mutation at the 3 ′ end predicting a Kir6.2 protein with 
an addition of 104 amino acids at the C-terminal end 
( fig. 1 b;  table 1 ).
 The majority of mutations detected in  ABCC8 and 
 KCNJ11 in this study (38/64) have not previously been 
described. These novel mutations are summarized in 
 table 1 . To validate a pathogenic effect of novel muta-
tions we performed in silico predictions using proven 
software programs ( table 1 ). As expected, a clearly del-
eterious effect was predicted for all frameshift, nonsense 
and splicing mutations. The ‘silent’ mutation c.1176G>A 
p.(0=) of  ABCC8 in fact was predicted to affect splicing 
of exon 7, since c.1176G is the last nucleotide of exon 7 
and within the consensus sequence at the splice donor 
site. Consistent prediction of a high probability of being 
pathogenic was obtained from PolyPhen-2 and Muta-
tionTaster2 for 10 of 14 and 4 of 6 novel missense mu-
tations in  ABCC8 and  KCNJ11 , respectively ( table  1 ). 
For 4 missense mutations ( ABCC8 : p.I1404M, p.
V1430A;  KCNJ11 : p.A96T, p.P340H), the scores calcu-
lated by PolyPhen-2 were somewhat weaker than those 
from MutationTaster2, while discrepant prediction re-
sults were only received for 2 novel variants in the 
 ABCC8 gene, namely p.V17A and p.I148T. The former 
was identified in a patient with a diffuse CHI type as 
proved by histology, who carried a splice site mutation 
on the other  ABCC8 allele, thus supporting the patho-
genetic relevance of this change. The latter variant 
( ABCC8 : p.I148T) was found as a heterozygous change 
only in an infant who is currently being treated with a 
somatostatin analogue and who responded well, and 
further imaging diagnosis was not performed. The vari-
ant was transmitted from the healthy father, thus allow-
ing no definite classification. All other novel sequence 
changes listed in  table 1 (including the latter 2 with the 
ambiguous prediction results) showed a segregation 
pattern within the respective families that corresponded 
with the clinically diagnosed CHI type (biparental trans-
mission of mutations in diffuse CHI and recessive in-
heritance; heterozygous paternally inherited mutation 
in focal CHI), thus supporting their pathogenic signifi-
cance ( table 2 ).
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 Clinical Data 
 Comprehensive clinical data, including birth deliv-
ery, birth weight related to gestational age, time of man-
ifestation, DZX responsiveness and type of CHI deter-
mined by localization diagnostics and histology, were 
available from 47 affected individuals from the 61 fam-
ilies in whom K ATP channel mutations could be identi-
fied. For the remaining 14 patients, only partial infor-
mation was available. In 37% of patients (18/49), birth 
weight was large for gestational age, indicating fetal on-
set of CHI. Initial hypoglycemia was detected within the 
first hours of life in 95% of patients (58/61) and within 
10 days to 6 months in 5% (3/61;  table 3 ). A trial with 
DZX was performed in 53 patients, and only 12 were 
reported to be (partially) responsive. In 49 patients 
(80%), conclusive results from imaging and/or histolo-
gy were available. Twenty-five patients were diagnosed 
as having a diffuse form of CHI, while 21 exhibited a 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39
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c.2117-2A>T c.2698-2A>G c.3402+2T>C
exons 32–33 del exons 34–37 del
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c.2041-21G>A
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A96T R301G
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b
 Fig. 1. Mutation spectrum of  ABCC8 and  KCNJ11  in patients from 
the German CHI registry. Schematic outlines of the  ABCC8 gene 
( a ) and the single exon of  KCNJ11 ( b ) were adapted from Snider 
et al.  [33] . Missense mutations are shown above the exons, while 
nonsense and frameshift mutations, splice mutations and intra-
genic deletions are shown below the exons.  ABCC8 exons encod-
ing the 2 nucleotide-binding domains are shaded ( a ), and the 
transmembrane-spanning domains encoded by the single exon of 
 KCNJ11 are indicated by black bars ( b ). Dominant mutations are 
indicated in bold letters, and unclassified mutations (recessive or 
dominant) are underlined. 
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Table 1.  Novel  ABCC8 and  KCNJ11 mutations detected in the cohort
Gene cDNA Predicted protein Mutation type  In silico prediction2 Genetic 
status
Frequency3
 Poly
Phen-2
Mutation 
Taster
ABCC81
Exon 1 c.50T>C p.(V17A) missense 0.194 0.9957 c-htz 1
Exon 3 c.392A>C p.(N131T) missense 0.990 0.9999 c-htz 1
Exon 4 c.443T>C p.(I148T) missense 0.211 0.9998 htz pat 1
Exon 6 c.835_851dup p.(I287fs*78) frameshift 1 htz pat 1
Exon 7 c.1176G>A p.(0=)4 splice site 1 htz pat 1
Intron 8 c.1333-1G>A p.0?4 splice site 1 htz pat 1
Exon 10 c.1530G>T p.(K510N) missense 1 0.9999 htz pat 1
Exon 10 c.1598T>C p.(L533P) missense 0.997 0.9999 hmz 1
Intron 11 c.1672-9T>A p.0? splicing 0.9999 c-htz 1
Intron 15 c.2117-2A>T p.0? splice site 1 c-htz 2
Exon 16 c.2123_2191del p.(L708_M730del) in-frame deletion n.a. hmz 1
Exon 16 c.2169_2171del p.(L724del) in-frame deletion 0.9999 htz mat; dom 1
Exon 16 c.2180T>G p.(L727R) missense 1 0.9999 c-htz 1
Intron 19 c.2394-1G>A p.0? splice site 1 c-htz; htz pat 3
Intron 22 c.2698-2A>G p.0? splice site 1 c-htz 1
Intron 27 c.3402+2T>C p.0? splice site 1 htz pat 1
Exon 29 c.3636_3637dup p.(T1213Hfs*8) frameshift 1 hmz 1
Exon 30 c.3739T>A p.(W1247R) missense 1 0.9999 c-htz 1
Exon 30 c.3743del p.(L1248Rfs*18) frameshift 1 c-htz 1
Exon 32 c.3871-31_3994del p.0? exon deletion n.a. c-htz 1
Exon 33 c.4038del p.(I1347Sfs*4) frameshift 1 htz pat 1
Exon 34 c.4123-?_4548+?del p.0? exon deletion n.a. c-htz 1
Exon 34 c.4126_4131del p.(G1376_I1377del) in-frame deletion n.a. htz pat 1
Exon 34 c.4135G>A p.(G1379S) missense 1 0.9999 htz mat 1
Intron 34 c.4202-2A>T p.0? splice site 1 c-htz 1
Exon 35 c.4212C>G p.(I1404M) missense 0.436 0.9994 htz pat; dom 1
Exon 35 c.4214T>C p.(I1405T) missense 0.999 0.9999 c-htz 1
Exon 35 c.4256G>T p.(R1419L) missense 1 0.9999 c-htz 1
Exon 35 c.4289T>C p.(V1430A) missense 0.610 0.9942 htz pat; dom (?) 1
Exon 37 c.4453G>A p.(G1485R) missense 1 0.9999 htz 1
KCNJ111
Exon 1 c.118G>A p.(G40S) missense 1 0.9999 htz pat 1
Exon 1 c.286G>A p.(A96T) missense 0.687 0.9999 htz pat 1
Exon 1 c.350_352del p.(F117del) in-frame deletion 0.9999 c-htz 1
Exon 1 c.406C>A p.(R136S) missense 1 0.9999 c-htz 1
Exon 1 c.612C>A p.(D204E) missense 0.999 0.9999 htz pat 1
Exon 1 c.866G>T p.(G289V) missense 1 0.9999 de novo 1
Exon 1 c.1019C>A p.(P340H) missense 0.795 0.9879 c-htz 1
Exon 1 c.1097_1109delinsAG p.(G366Efs*128) frameshift n.a. htz mat; dom 1
 n.a. = Not applicable; c-htz = compound heterozygous; htz = 
heterozygous; hmz = homozygous; dom = dominant inheritance; 
de novo = de novo occurrence (not detected in parents); pat = pa-
ternal inheritance; mat = maternal inheritance. 
1 ABCC8 reference transcript ENST00000302539 including the 
alternative codon in exon 17; KCNJ11 reference transcript 
ENST00000339994. 
2 Scores refer to the probability of a damaging effect using pre-
diction programmes. For PolyPhen-2, HumanVar scores are 
shown; scores are evaluated as 0.000 (most probably benign) to 
0.999 (most probably damaging). For MutationTaster, scores de-
scribe the probability of the prediction, i.e. a value close to 1 indi-
cates a high ‘security’ of the prediction. 
3 Frequency of occurrence in unrelated patients. 
4 According to Human Genome Variation Society nomencla-
ture: p.(0=) = probably no protein is produced or synonymous 
substitution; p.0? = effect on protein unknown.
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Table 2.  Summary of clinical and genetic results of  ABCC8 and  KCNJ11 mutation-positive patients
Patient 
No.
Gene cDNA Predicted protein Genetic 
status
Parental 
origin
Birth 
delivery
Birth 
weight
Manife-
station1
Maximum 
glucose 
uptake, 
mg/kg/min
DZX2 Sur-
gery
Histology 
ABCC8
33 exon 3 c.392A>C p.(N131T) c-htz pat preterm LGA neonatal 20 ++ no n.d.
exon 21 c.2524C>T p.(R842*) c-htz mat
46 exon 7 c.1063G>A p.(A355T) c-htz n.d. preterm LGA neonatal n.a. ++ no n.d.
exon 36 c.4372G>A p.(A1458T) c-htz n.d.
41 exon 35 c.4214T>C p.(I1405T) c-htz pat preterm LGA neonatal n.a. ++ no diffuse4
intron 32 c.3992-9G>A p.0?3 c-htz mat
37 exon 16 c.2180T>G p.(L727R) c-htz pat term LGA infantile >10 + yes diffuse
exon 32 c.3871-31_3994del p.0? c-htz mat
34 exon 30 c.3743del p.(L1248Rfs*18) c-htz pat preterm AGA neonatal >10 + no diffuse4
intron 32 c.3992-9G>A p.(?) c-htz mat
7 exon 1 c.50T>C p.(V17A) c-htz pat term LGA neonatal >20 – yes diffuse
intron 19 c.2394-1G>A p.0? c-htz mat
40 exon 6 c.892C>T p.(R298C) c-htz pat preterm LGA neonatal n.a. – yes segmental 
mosaic
exon 37 c.4435G>A p.(G1479R) c-htz mat
11 exon 8 c.1332G>T p.(Q444H) c-htz n.d. term LGA neonatal 10 – yes diffuse
intron 34 c.4202-2A>T p.0? c-htz n.d.
3 exon 8 c.1332G>T p.(Q444H) c-htz n.d. term LGA neonatal <10 – yes n.d.
exon 13 c.1879del p.(H627Mfs*20) c-htz n.d.
26 exon 12 c.1792C>T p.(R598*) c-htz pat preterm LGA neonatal n.a. – no diffuse4
intron 15 c.2117-2A>T p.0? c-htz mat
24 intron 19 c.2394-1G>A p.0? c-htz pat preterm LGA neonatal >10 – no diffuse4
exon 30 c.3751C>T p.(R1251*) c-htz mat
19 intron 22 c.2698-2A>G p.0? c-htz pat term AGA neonatal >10 – yes diffuse
intron 11 c.1672-9T>A p.0? c-htz mat
42 exon 35 c.4256G>T p.(R1419L) c-htz pat term n.a. neonatal n.a. – yes diffuse
exon 34 c.4123-?_4548+? p.0? c-htz mat
2 exon 10 c.1617T>A p.(Y539*) c-htz n.d. n.a. n.a. neonatal n.a. n.a. yes diffuse
exon 30 c.3739T>A p.(W1247R) c-htz n.d.
5 exon 10 c.1598T>C p.(L533P) hmz bipar term LGA neonatal n.a. n.a. no diffuse4
13 exon 16 c.2123_2191del p.(L708_M730del<9) hmz bipar term n.a. neonatal n.a. n.a. no n.d.
22 exon 29 c.3636_3637dup p.(T1213Hfs*8) hmz bipar preterm AGA neonatal >10 – no diffuse4
50 exon 29 c.3643C>T p.(R1215W) hmz n.d. term AGA neonatal >10 + no diffuse4
21 exon 6 c.835_851dup p.(I287Lfs*78) htz pat preterm LGA neonatal 20 – yes focal
31 intron 7 c.1176+2T>C p.0? htz pat term n.a. neonatal n.a. n.a. yes focal
10 exon 8 c.1332G>T p.(Q444H) htz pat term AGA neonatal >20 – yes focal
18 exon 8 c.1332G>T p.(Q444H) htz pat term LGA neonatal >10 – yes focal
29 intron 8 c.1333-1G>A p.0? htz pat term AGA neonatal n.a. – yes focal
38 exon 10 c.1530G>T p.(K510N) htz pat term AGA infantile n.a. – yes focal
39 exon 12 c.1792C>T p.(R598*) htz pat term AGA neonatal n.a. – yes focal
43 intron 14 c.2041-21G>A p.0? htz pat term n.a. neonatal n.a. – yes focal
45 intron 15 c.2117-2A>T p.0? htz pat term AGA neonatal n.a. – yes focal
25 intron 19 c.2394-1G>A p.0? htz pat term LGA neonatal n.a. n.a. yes focal
32 exon 24 c.2860C>T p.(Q954*) htz pat term AGA neonatal n.a. ++ yes focal
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Table 2.  (continued)
Patient 
No.
Gene cDNA Predicted protein Genetic 
status
Parental 
origin
Birth 
delivery
Birth 
weight
Manife-
station1
Maximum 
glucose 
uptake, 
mg/kg/min
DZX2 Sur-
gery
Histology 
16 exon 33 c.4024C>T p.(Q1342*) htz pat term AGA neonatal >10 – yes focal
27 exon 33 c.4038del p.(I1347Sfs*4) htz pat term AGA neonatal n.a. – yes focal
20 exon 34 c.4126_4131del p.(G1376_I1377del) htz pat term AGA neonatal >10 – yes focal
47 exon 34 c.4135G>C p.(G1379R) htz pat term AGA neonatal n.a. – yes focal
49 exon 35 c.4241C>T p.(P1414L) htz pat term AGA neonatal >10 – yes focal
15 exon 7 c.1176G>A p.(0=)3 htz pat preterm AGA neonatal >10 – no diffuse4
30 exon 25 c.(3133_3152del) p.(T1045Lfs*63) htz pat term AGA neonatal >10 – no diffuse4
23 exon 35 c.4289T>C p.(V1430A) htz pat preterm AGA neonatal n.a. – no nonfocal5
35 exon 4 c.443T>C p.(I148T) htz pat term AGA infantile <10 – no n.d.
9 intron 25 c.3165+1G>A p.0? htz pat term AGA neonatal n.a. n.a. no n.d.
4 intron 27 c.3402+2T>C p.0? htz pat term AGA neonatal >10 – no n.d.
1 exon 35 c.4212C>G p.(I1404M) htz pat term AGA neonatal n.a. n.d. no n.d.
17 exon 37 c.4519G>A p.(E1507K) htz dom pat term AGA neonatal n.a. ++ no diffuse4
14 exon 34 c.4135G>A p.(G1379S) htz dom mat preterm LGA neonatal 20 ++ no diffuse4
6 exon 16 c.2169_2171del p.(L724del) htz dom mat preterm n.a. neonatal n.a. – yes diffuse
36 exon 37 c.4519G>A p.(E1507K) htz de novo term AGA neonatal n.a. ++ yes diffuse
48 exon 37 c.4519G>A p.(E1507K) htz de novo term AGA neonatal n.a. – yes diffuse
8 exon 8 c.1332G>T p.(Q444H) htz n.d. term AGA neonatal n.a. – yes focal
44 exon 16 c.2146G>T p.(G716C) htz n.d. term n.a. neonatal n.a. – yes diffuse
28 exon 16 c.2176G>A p.(A726T) htz n.d. preterm AGA neonatal n.a. – no diffuse4
12 exon 37 c.4453G>A p.(G1485R) htz n.d. term AGA neonatal >10 – no diffuse4
KCNJ11
57 exon 1 c.350_352del p.(F117del) c-htz bipar term n.a. neonatal n.a. – yes n.a.
exon 1 c.1019C>A p.(P340H) c-htz bipar
52 exon 1 c.185C>T p.(T62M) hmz bipar term LGA neonatal n.a. – yes diffuse
54 exon 1 c.185C>T p.(T62M) hmz bipar term LGA neonatal n.a. – no diffuse4
51 exon 1 c.118G>A p.(G40S) htz pat term LGA neonatal n.a. – yes focal
55 exon 1 c.286G>A p.(A96T) htz pat term AGA neonatal n.a. – yes focal
56 exon 1 c.612C>A p.(D204E) htz pat preterm AGA neonatal n.a. – yes focal
59 exon 1 c.844G>A p.(E282K) htz pat term n.a. neonatal n.a. – yes focal
53 exon 1 c.901C>G p.(R301G) htz pat preterm AGA neonatal n.a. – yes focal
60 exon 1 c.1097_1109delinsAG p.(G366Efs*128) htz dom mat n.a. n.a. neonatal n.a. ++ no n.d.
61 exon 1 c.866G>T p.(G289V) de novo de novo n.a. n.a. neonatal n.a. ++ no n.d.
58 exon 1 c.406C>A p.(R136S) htz n.d. n.a. n.a. neonatal n.a. n.a. no n.d.
 c-htz = Compound heterozygous; htz = heterozygous; hmz = homozy-
gous; dom = dominant inheritance; de novo = de novo occurrence (not de-
tected in parents); mat = maternal inheritance; pat = paternal inheritance; 
bipar = biparental; AGA = appropriate for gestational age; LGA = large for 
gestational age; n.a. = not available; n.d. = not done. 
1 Neonatal: 0–30 days of life; infantile: 1–12 months.
2 + = Partially responsive to DZX; ++ = responsive to DZX; – = resistant 
to DZX. 
3  According to Human Genome Variation Society nomenclature: 
p. (0=) = probably no protein is produced or synonymous substitution; p.0? 
= effect on protein unknown. 
4 Only imaging was performed. 
5 Positron emission tomography/CT showed an irregular pattern with-
out further histology.
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focal type. In 1 patient with compound heterozygosity 
of missense mutations in  ABCC8 , an unusual histology 
distributed over the pancreas was found. Thirty-five af-
fected individuals underwent surgery, which was subto-
tal pancreatectomy in 7 and partial pancreatectomy or 
excision of a focus in 28 patients ( table 2 ). 
 Response to Medical Treatment 
 DZX sensitivity was reported in 12 infants. In 5 in-
fants, a known or presumed dominant mutation within 
 ABCC8 or  KCNJ11 was detected ( ABCC8 : 2× p.E1507K, 
p.G1379S;  KCNJ11 : p.G289V, p.G366Efs * 128). Four pa-
tients had compound heterozygous mutations of  ABCC8. 
In 3 of them, one allele carried a missense mutation, and 
in 2 of them, one allele was the Ashkenazi founder muta-
tion c.3992-9G>A, which is known to be associated with 
a more variable phenotype  [38] . Two of these individuals 
received octreotide in addition to DZX to achieve suffi-
cient metabolic control, thus indicating that there was 
only partial DZX sensitivity. One patient who was re-
ported as DZX responsive before surgery had a pater-
nally inherited  ABCC8 nonsense mutation (c.2860C>T, 
p.Q954 * ) with a proven focal type and relatively mild 
manifestation.
 Genotype-Phenotype Correlations  
 Fifteen patients from unrelated families in this cohort 
harbored compound heterozygous mutations, including 
8 known and 17 novel mutations, and 6 patients were ho-
mozygous with clinically unaffected carrier parents with 
known or suspected consanguinity in all of them. This 
genetic constellation leads to a clear diagnosis of autoso-
mal recessive inheritance of the disease in 34% of the fam-
ilies. Such a genotype is suggestive of a diffuse form of 
CHI, which was further supported in all of the patients 
who underwent imaging or surgery (n = 16).
 A single heterozygous mutation was recognized in 40 
unrelated patients (66%), including 11 known and 25 
novel mutations. In 23 cases, the mutation was inherited 
from a clinically unaffected father, a constellation that is 
generally suggestive of a focal form of CHI. Concomi-
tantly, the observed genetic changes included 13 putative 
Table 3.  Clinical presentation of patients with mutations in  ABCC8 or  KCNJ11 
Genotype Number Birth weight First onset of 
hypoglycemia1
DZX response Familial 
cases
Heterozygote with 
 paternal inheritance
ABCC8 
23
KCNJ11
5
ABCC8 
LGA
AGA
n.a.
KCNJ11
LGA
AGA
n.a.
3/23
18/23
2/23
1/5
3/5
1/5
ABCC8
neonatal
infantile
KCNJ11
neonatal 
21/23
2/23
5/5
ABCC8
responsive
KCNJ11
responsive
2/23
0/5
0/23
0/5
Recessive/biparental 
inheritance
ABCC8 
24
KCNJ11
5
ABCC8
LGA
AGA
n.a.
KCNJ11
LGA
AGA
n.a.
11/24
9/24
4/24
2/5
0/5
3/5
ABCC8
neonatal
infantile
KCNJ11
neonatal
23/24
1/24
5/5
ABCC8
partially responsive
responsive
KCNJ11
responsive
3/24
4/24
1/5
0/24
0/5
Dominant inheritance ABCC8 
3
KCNJ11
1
ABCC8
LGA
AGA
n.a. 
KCNJ11
n.a.
1/3
1/3
1/3
1/1
ABCC8
neonatal
KCNJ11
neonatal
3/3
1/1
ABCC8
responsive
KCNJ11 
responsive
2/3
1/1
3/3
1/1
 AGA = Appropriate for gestational age; LGA = large for gestational age; n.a. = not available. 
1 Neonatal: 0–30 days of life; infantile: 1–12 months.
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‘null’ mutations, 9 missense mutations and 1 in-frame de-
letion; of the latter two groups, 6 are known as recessive 
mutations while 4 were novel ones. All of these patients 
who had a focal type of CHI inherited a monoallelic mu-
tation from their healthy fathers, and the diagnosis was 
confirmed by imaging and/or pancreatic histology highly 
suggestive of recessive mutation types that are associated 
with a focal form of CHI. 
 The  ABCC8 missense mutations p.I1404M and p.
V1430A, which were observed as paternally inherited 
heterozygous changes in 2 unrelated patients, were called 
unclassified (recessive or dominant) because of insuffi-
cient clinical data from the patients and their fathers. The 
individual who carried the paternally inherited novel 
 ABCC8 change p.I1404M had severe hypoglycemic epi-
sodes during infancy and childhood that resolved spon-
taneously during adolescence. The other novel  ABCC8 
mutation, c.1176G>A (with probable splicing effect) was 
observed as a paternally inherited heterozygous change in 
a patient with a diffuse CHI type by imaging diagnostics. 
Inheritance of the  ABCC8 mutation p.G716C in 2 further 
siblings was shown to be nonmaternal, suggesting pater-
nal transmission. However, clinical data and DNA from 
the father were not available; therefore, this mutation was 
also called unclassified (recessive or dominant). In these 
cases, we cannot exclude the possibility that the mutation 
acts in a dominant fashion with incomplete penetrance or 
that a second maternal mutation was missed. 
 Maternal inheritance was shown for the novel  ABCC8 
mutation p.G1379S, which was classified as dominant 
because the mother was pancreatectomized during in-
fancy and a diffuse form of CHI was confirmed by im-
aging in the patient. Two novel heterozygous mutations 
( ABCC8 : p.L724del;  KCNJ11 : p.G366Efs * 128) showed 
dominant maternal inheritance, because the mothers 
and/or their progeny were affected, and the missense 
mutation p.G289V in  KCNJ11 was observed as a hetero-
zygous de novo alteration, which is rather indicative of 
a dominant mutation type. CHI was diagnosed in the 
patient at the age of 6 months, when the patient  presented 
with hypoglycemia and seizures. The patient responded 
to medical treatment with DZX. Finally, the known 
dominant mutation p.E1507K was detected 3 times in 
this cohort including 2 de novo genetic events. Diffuse 
type was confirmed by imaging and histology. 
 In 3 cases, the parent of origin of a heterozygous mutation 
could not be determined. These mutations included 3 mis-
sense changes in the  ABCC8 gene. The first was p.Q444H, a 
known and recurrent mutation considered to act as a reces-
sive allele. In the patient, a focal lesion was detected by imag-
ing and confirmed by histology, suggesting paternal trans-
mission of the mutation. The following 2 missense muta-
tions were classified tentatively as dominant mutations: 
p. A726T, which was previously described as a variant of un-
certain clinical significance  [8] , and the novel change 
p. G1485R, which is suggested to be a dominant mutation 
because of its localization within a cluster of dominant muta-
tions in conjunction with a diffuse type of CHI in the patient. 
 Discussion 
 CHI represents a group of clinically, genetically and 
morphologically heterogeneous entities  [39] . To date, de-
fects in K ATP channel function have accounted for the ma-
jority of cases in which a genetic diagnosis can be estab-
lished, and they are often associated with a severe expres-
sion of the disease. Since these patients are at risk of 
hypoglycemic brain damage and subsequent significant 
neurological sequelae, rapid diagnosis and disease man-
agement are mandatory  [4, 40–42] . In our cohort, 61 out 
of 136 investigated unrelated patients (45%) carried mu-
tations in either  ABCC8  or KCNJ11. This proportion cor-
responds quite well with previously published cohorts  [2, 
32, 36] . It has been shown that among patients selected 
for early onset of the disease and DZX resistance, the pro-
portion of cases related to K ATP channel mutations may 
be up to 91%  [30, 33] .
 Genetic testing may be a useful tool not only for con-
firming the diagnosis of CHI but also for distinguishing 
between the different genetic and biological mechanisms 
underlying CHI, thus having an impact on clinical man-
agement and genetic counseling of affected families  [9, 
33, 37, 43, 44] . In the cohort presented here, biparental 
inheritance of  ABCC8/KCNJ11 gene mutations was 
found in 21 of 61 K ATP CHI patients (34%), with two 
thirds of them carrying a compound heterozygous geno-
type. The majority of patients with proven recessive 
 ABCC8/KCNJ11 -related disease showed severe pheno-
types, including unresponsiveness to medical treatment 
and diffuse pancreatic involvement. A paternally inher-
ited heterozygous recessive mutation suggestive of a fo-
cal form of CHI was detected in 23 of 61 patients (38%). 
Currently, these patients benefit most from genetic test-
ing because after visualization of the focus by modern 
imaging methods, localized pancreatic surgery is able to 
cure them  [28, 45] . In this cohort, 21 out of 23 patients 
with a heterozygous mutation inherited from the unaf-
fected father were confirmed to have focal CHI, and all 
proven focal cases had the typical genetic constellation, 
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thus confirming a high specificity and sensitivity, respec-
tively, in terms of the correct classification of the CHI 
type on the basis of genetic test results. In 5 of 61 cases a 
dominant mutational effect was evident, either because 
of a known dominant mutation or dominant segregation 
of the phenotype with the mutation within a family. Two 
additional mutations can be tentatively assigned as dom-
inant ones, i.e. the  ABCC8 mutation p.G1485R, which 
was observed in a sporadic case with insufficient clinical 
data about the parents, and the  KCNJ11 mutation p.
G289V, which was observed as a de novo event in a spo-
radic case. In 7 patients, the classification of the identi-
fied mutations was less obvious because of conflicting 
results from the prediction programs, a phenotype that 
was inconsistent with the genetic results or unavailabil-
ity of parental genotypes or phenotypes. Particularly for 
the novel variant p.I148T and the previously described 
p.A726T, it also has to be considered that the identified 
variants might be nonpathogenic. This emphasizes the 
need to integrate results from the in silico prediction 
with segregation analysis and clinical phenotype in order 
to obtain a reliable classification of mutations that may 
be used in future for genetically based prognosis and de-
cision-making. Currently, it is not possible to unequivo-
cally predict the functional impact of the large number 
of private missense mutations. Whereas the majority of 
nonsense, frameshift and splice site mutations, as well as 
exon deletions, can be presumed to represent functional 
null alleles, suggesting that they act in a recessive fashion, 
the interpretation of novel missense mutations or small 
in-frame deletions/insertions may be challenging. This 
illustrates the need for large patient registries that collect 
and integrate clinical and genetic data of many CHI pa-
tients in order to establish genotype-phenotype correla-
tions that can be incorporated in future individualized 
treatment decisions. There is also a possibility that muta-
tions in the investigated genes (e.g. intronic or promoter 
changes) can be missed by the employed mutation 
screening methods, thus explaining apparent inconsis-
tencies between genotype and phenotype. Indeed, it has 
recently been reported, for example, that a deep intronic 
mutation detected by next-generation sequencing is able 
to create a cryptic splice site and an out-of-frame pseu-
doexon in the  ABCC8 transcript  [46] . 
 In the course of this study, we observed inheritance 
patterns that do not exactly follow the classical recessive 
or dominant mode, thus further expanding the genetic 
complexity of CHI. In 1 patient, compound heterozygos-
ity was detected for the  ABCC8 missense mutations 
p. R298C and p.G1479R. The former was inherited from 
an unaffected father and has been recently classified as a 
recessive mutation  [33] . The latter mutation, p.G1479R, 
inherited from the mother with lack of clinical data, has 
been previously identified in independent families with 
dominant inheritance, albeit with incomplete pene-
trance, and it was reported to be associated with a milder, 
DZX-responsive CHI phenotype  [19, 36, 47] . Compound 
heterozygosity for a recessive and a mild dominant 
 ABCC8 missense mutation was associated with a rela-
tively severe disease manifestation in our patient. A sim-
ilar genetic situation, e.g. coinheritance of a dominant 
and a predicted recessive missense mutation in  ABCC8 , 
has previously been reported in another patient with a 
much more severe phenotype compared to individuals 
with the sole presence of the dominant mutation  [48] . In 
addition, we detected homozygosity for the  KCNJ11 mis-
sense mutation p.T62M in 2 patients from independent 
consanguineous families of Turkish descent. This muta-
tion has been recently proposed as a dominant one as-
sociated with a DZX-responsive phenotype  [33] . The 
parents of our patients had no obvious phenotype, but 
unfortunately, no detailed clinical data were available 
from them to exclude a minor phenotypic effect of the 
mutation in the heterozygous state. In the homozygous 
state, as observed in our patients, the phenotype was se-
vere and indistinguishable from recessive cases with oth-
er genotypes. This suggests that the  KCNJ11 mutation 
p.T62M represents an intermediate mutation type that 
may occur as a recessive allele and as reflected by semi-
dominant inheritance as a dominant incompletely pen-
etrant mutation, depending on the genetic context  [49] . 
Finally, the novel heterozygous missense mutation 
p.G716C in  ABCC8 was detected in 2 siblings affected 
with a diffuse form of CHI. This mutation was not trans-
mitted from the mother, as determined by routine ge-
netic testing. Although the father was not available for 
testing, paternal inheritance has been presumed because 
both children are affected. Different missense mutations 
at codon position 716 in  ABCC8 have been classified as 
recessive or dominant  [17, 30] , which makes prediction 
of the mutation type for p.G716C difficult, in particular, 
because we cannot exclude an as yet undetected mater-
nally derived second mutation.
 In contrast to small sequence changes, intragenic sin-
gle or multiple exon deletions in the  ABCC8 gene are not 
very common. They have been previously observed in in-
dependent cohorts at low frequencies in 2 of 89 patients 
(2.2%) with  ABCC8/KCNJ11 defects  [30] and in 4 of 125 
DZX-unresponsive patients (3.2%)  [50] . We observed a 
similar frequency of 2 of 61 patients (3.3%) with  ABCC8/
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KCNJ11 mutations in our cohort. Both patients were 
compound heterozygous for the deletion and a missense 
mutation in the  ABCC8 gene. In 2 other large cohorts, one 
multiple exon deletion was identified in 109 patients 
(0.9%)  [32] and a single duplication of 4 exons of the 
 ABCC8  gene was identified in 1 of 265 patients (0.4%) 
with  ABCC8/KCNJ11 mutations  [33] . 
 DZX is regarded as first-line medication in CHI. Most 
cases with this diagnosis are therefore at least trialled on 
this drug to determine DZX responsiveness. Since the 
pharmacological effect of DZX is based upon binding of 
the compound to the extracellular domain of the K ATP 
channel and modification of its conductivity, it is obvious 
that the complete or near-complete lack of one of the 
channel’s components is generally associated with resis-
tance to this drug. In this cohort, DZX sensitivity was re-
ported in only 12 patients, 5 of whom had a known or 
presumed dominant mutation. This is consistent with 
previous experience and with the proposed biological 
mechanism of dominant mutations which are assumed to 
lead to functional impairment but not complete absence 
of K ATP channels. Four patients reported to be (partially) 
DZX responsive instead were recessive cases with com-
pound heterozygosity for mutations in  ABCC8. Notably, 
in all of them there was at least one allele that might be 
compatible with the expression of a protein that exhibits 
residual function, namely different missense mutations 
and in 2 cases the known Ashkenazi founder mutation 
c.3992-9G>A, which is known to be associated with a 
variable phenotype. In the case of a patient with focal CHI 
and a paternally inherited  ABCC8 nonsense mutation, we 
have no definite explanation for the observed DZX re-
sponse.
 In conclusion, genetic analysis of the K ATP channel 
genes  ABCC8 and  KCNJ11 revealed mutations in 45% 
of patients from an unselected CHI patient cohort. No 
major recurrent mutation indicative of a founder effect 
was detected in this cohort, which was mainly com-
posed of patients from Central Europe. Rapid genetic 
testing in infants with DZX-resistant CHI appears to be 
a useful tool for determining the best individual clinical 
management. In particular, the presence of a heterozy-
gous paternally transmitted recessive mutation has a 
very good sensitivity and specificity in predicting the 
focal form of CHI, which can be cured by lesional resec-
tion. Concerted efforts to integrate clinical and genetic 
results in large registries and databases are necessary to 
further improve the classification of rare mutations and 
their impact on individualized treatment and genetic 
counseling of families. 
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